Peptide Library

Human study PLS-00146

Exploring the Relationship Between Thymosin β4 Protein and First Myocardial Infarction on the Basis of Proteomics.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Exploring the Relationship Between Thymosin β4 Protein and First Myocardial Infarction on the Basis of Proteomics.primary · Journal of the American Heart Association · 2025-02-14 · PMID 39950438 · DOI

Design and participants

Design
Case-control study
Population
Patients with first-onset acute myocardial infarction and age- and sex-matched healthy controls (discovery set), plus an ELISA validation set of AMI patients and healthy individuals.
Conditions
Acute myocardial infarction
Setting
Not stated; trial registered in the Chinese Clinical Trial Registry.
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (sponsor not named in record)
Authors’ conflicts
Not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound administered.

    The authors concluded (paraphrased): The authors concluded that plasma TMSB4 has diagnostic value for first-onset myocardial infarction and may be a potential diagnostic marker.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous Tβ4 was measured as a biomarker. No Tβ4 was administered, so the study gives no information on treatment effects or safety.
    • abstract only: Only the abstract is available, and the results section is garbled, so the numeric findings cannot be read.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 39950438, abstract (Conclusions) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 39950438, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 39950438, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 39950438, abstract (Methods, sentences 2-3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 39950438, abstract (Methods, sentences 1 and 3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 39950438, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).